AZNASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 76.96 $ 0.65 (0.85 %)    

Wednesday, 08-May-2024 15:59:58 EDT
QQQ $ 440.83 $ 0.37 (0.08 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.04 $ 0.00 (0 %)
GLD $ 214.13 $ -0.57 (-0.27 %)
$ 76.97
$ 76.77
$ 76.95 x 100
$ 77.00 x 300
$ 76.62 - $ 77.15
$ 59.55 - $ 77.16
5,059,790
na
120.23B
$ 0.56
$ 7.03
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 astrazeneca-pulls-plug-on-vaxzevria-covid-19-vaccine-amid-surplus-of-updated-vaccines

It is worth noting that AstraZeneca has previously conceded in court documents that Vaxzevria can induce side effects such as b...

 astrazeneca-withdrawing-its-covid-vaccine-worldwide

https://www.telegraph.co.uk/news/2024/05/07/astrazeneca-withdrawing-covid-vaccine/

Core News & Articles

As part of the Additional Investment, AstraZeneca subscribed today for 10,000,000 "class A" convertible preferred share...

Core News & Articles

Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development wi...

Core News & Articles

New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitaliz...

 federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-companies-like-novo-nordisk-astrazeneca

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, a...

 astrazeneca-admits-its-covid-19-vaccine-may-cause-blood-clotting-side-effect-in-very-rare-case-but-causal-mechanism-unknown

Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and b...

 double-good-news-for-astrazenecas-breast-cancer-drugs

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

 on-sunday-telegraph-reported-that-astrazeneca-admits-for-first-time-in-court-documents-its-covid-vaccine-can-cause-rare-side-effect-the-company-is-being-sued-in-class-action-over-claims-its-vaccine-caused-death-and-serious-injury-in-dozens-of-cases

https://www.telegraph.co.uk/news/2024/04/28/astrazeneca-admits-covid-vaccine-causes-rare-side-effect/

Core News & Articles

Daiichi Sankyo and AstraZeneca's ENHERTU also demonstrated a clinically meaningful progression-free survival improvement i...

 will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

 bmo-capital-maintains-outperform-on-astrazeneca-raises-price-target-to-82

BMO Capital analyst Etzer Darout maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $80 t...

Core News & Articles

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuca...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION